Upward Move: Jeremy Bender

Share this article:
Upward Move: Jeremy Bender
Upward Move: Jeremy Bender

Jeremy Bender
Chief Business Officer, Sutro Biopharma

California-based biotech Sutro Bio­pharma has recruited some deal-making expertise, bringing on Jeremy Bender, previously of Allos Therapeutics, as their chief business officer. In May of this year, Sutro's protein-synthesis platform garnered noticeable praise from venture capital and received $16.5 million in financing.

Bender intends to continue that transition from biotech to the big market. At Allos, he oversaw the company's buyout by Spectrum Pharmaceuticals. After that acquisition, Spectrum has projected higher cost savings and revenue. Bender was also involved in the collaboration between Allos and Mundipharma on lymphoma therapy Folotyn.

“At Allos,” he says, “I learned a lot about deal-making and the transition from the clinical to commercial stage. It was a rewarding experience.”

After a win with Allos, Bender sees a promising technology platform at Sutro and hopes to replicate his previous success. “Sutro has developed unparalleled capabilities, and is ready for the next phase of its growth,” he explains. Bender also notes the company now plans to focus on antibody drug conjugates.

Dr. Bender's value for Sutro will be in his understanding of how to cultivate commercial insights within high science. To that end, he plans to collaborate with other large drug manufacturers in an effort to foster growth. Sutro has announced one collaboration with Pfizer—to develop peptide-based therapeutics—which began in January of last year.

Bender's background, with a graduate degree in immunology and an MBA from MIT, marries his clinical and commercial interests—and it aligns closely with the fast-paced biotech industry.  “The ability to develop novel technologies and push the limits of science and technology are easier in small companies,” he quips. “That's due to the size and scale of the organization, but it's also because of the kind of individuals which are excited by a small company.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Upward Move

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Upward Move

Upward Move: Michael A. Griffith

Upward Move: Michael A. Griffith

Michael A. Griffith, Executive vice president, inVentiv Health

Upward Move: Pam Hamlin

Upward Move: Pam Hamlin

Pam Hamlin, Global president, Arnold Worldwide

Upward Move: Maggie Helmig

Upward Move: Maggie Helmig

Maggie Helmig, EVP, global brand lead, Ogilvy CommonHealth